Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) has been assigned a consensus recommendation of "Hold" from the five ratings firms that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $38.67.
Several equities research analysts have recently issued reports on PHAR shares. Zacks Research lowered shares of Pharming Group from a "hold" rating to a "strong sell" rating in a research report on Friday, July 31st. Weiss Ratings restated a "sell (d)" rating on shares of Pharming Group in a report on Friday, August 7th. Canaccord Genuity Group set a $38.00 price target on shares of Pharming Group in a research report on Wednesday, September 23rd. HC Wainwright reiterated a "buy" rating and issued a $37.00 price target on shares of Pharming Group in a report on Tuesday, September 22nd. Finally, Oppenheimer reissued an "outperform" rating on shares of Pharming Group in a research report on Thursday, July 30th.
Get Our Latest Research Report on PHAR
Pharming Group Stock Down 0.4%
Shares of NASDAQ:PHAR opened at $9.95 on Friday. The stock has a 50-day simple moving average of $11.21 and a 200-day simple moving average of $13.30. The stock has a market capitalization of $704.26 million, a P/E ratio of 82.92 and a beta of -0.04. Pharming Group has a 1 year low of $9.62 and a 1 year high of $21.34. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.31 and a current ratio of 3.01.
Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.06 by ($0.04). Pharming Group had a net margin of 2.51% and a return on equity of 3.40%. Equities analysts forecast that Pharming Group will post 0.22 earnings per share for the current year.
Institutional Investors Weigh In On Pharming Group
An institutional investor recently bought a new position in Pharming Group stock. MAC Alpha Capital Management LP bought a new stake in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The firm bought 2,148,144 shares of the company's stock, valued at approximately $29,838,000. Pharming Group accounts for 6.0% of MAC Alpha Capital Management LP's holdings, making the stock its 2nd biggest position. MAC Alpha Capital Management LP owned 3.03% of Pharming Group as of its most recent filing with the SEC. 0.03% of the stock is currently owned by institutional investors.
About Pharming Group
(
Get Free Report)
Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands, focused on developing and commercializing treatments for rare diseases. The company uses its expertise in protein replacement therapies and other biotechnology platforms to address conditions with limited treatment options.
Pharming's principal product is Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause severe swelling.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
